phase readout

NCT06630806: A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

RECRUITINGupdated 6d ago

community read0 votes

Sponsor: Sanofi. Phase: PHASE1. Conditions: Plasma Cell Myeloma Refractory

Data sources

last refreshed 28m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?